Enanta Pharmaceuticals has filed a lawsuit against the pharma giant Pfizer over claims of patent infringement involving its COVID-19 treatment Paxlovid. The company claims Pfizer’s use of nirmatrelvir, a protease inhibor that makes up one half of Paxlovid, is in violation of several patents. Instead of pulling the drug from the market, Enanta seeks “fair compensation.”
According to analysts, “We believe Enanta’s [MP] patent infringement lawsuit against Pfizer [MP, Risinger] is a surprising new development for Enanta’s COVID-19 antiviral program (EDP-235 protease inhibitor) that could bring additional volatility to the stock, presenting a “fine line” for Enanta to walk as the ‘235 program advances towards a Phase 2/3 trial; thus, we remain on the sidelines pending further clarity on next steps and possible outcomes.”
Click here to learn more.
(Source: Endpoints News, June 22nd, 2022)